CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia

Guo,Wenjian; Dong,Aishu; Xing,Chao; Lin,Xiaoji; Pan,Xiahui; Lin,Ying; Zhu,Baoling; He,Muqing; Yao,Rong‑Xing

doi:10.3892/ol.2014.2208

CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia

Authors:
- Wenjian Guo
- Aishu Dong
- Chao Xing
- Xiaoji Lin
- Xiahui Pan
- Ying Lin
- Baoling Zhu
- Muqing He
- Rong‑Xing Yao
View Affiliations

Affiliations: Department of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 0577, P.R. China
Published online on: June 2, 2014 https://doi.org/10.3892/ol.2014.2208
Pages: 825-830

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The antitumor effect of natural killer T cells has been reported in several studies analyzing the expression of CD1d on antigen‑presenting cells (APCs). Therefore, the present study questioned whether APCs may be abnormal in the peripheral blood (PB) of acute leukemia (AL) patients, particularly the levels of CD1d. To improve the understanding of the role of CD1d on APCs, the levels of CD1d on monocytes were analyzed in healthy controls, AL patients and AL patients with complete remission (CR). In addition, the correlation between the number of CD3+CD56+ T lymphocytes and levels of CD1d on monocytes was analyzed. Flow cytometry was used to determine the levels of CD1d on monocytes and lymphocytes. A significant decrease was observed in the levels of CD1d on monocytes in the PB of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients compared with the healthy controls. Simultaneously, significantly different levels of CD1d on monocytes were identified between the CR‑AML and the CR‑ALL patients; the levels of CD1d on monocytes remained low in the CR‑AML patients, while the levels of CD1d on monocytes recovered in the CR‑ALL patients. A significantly negative correlation was observed between the number of CD3+CD56+ T lymphocytes and the levels of CD1d on monocytes in AL patients. However, a significantly positive correlation was identified between the cytotoxicity of the CD3+CD56+ T lymphocytes and the levels of CD1d on monocytes. These results suggested that the significantly low levels of CD1d on monocytes may contribute to AML and ALL progression. In addition, a significant correlation was observed between the levels of CD1d on monocytes and the number/cytotoxicity of CD3+CD56+ T lymphocytes in AML and ALL patients.

View Figures

View References

1	Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011.
2	Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976.
3	Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 75:555–562. 1990.
4	Görgün G, Holderried TA, Zahrieh D, Neuberg D and Gribben JG: Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 115:1797–1805. 2005.
5	Görgün G, Ramsay AG, Holderried TA, et al: E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA. 106:6250–6255. 2009.
6	Dustin ML and Cooper JA: The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol. 1:23–29. 2000.
7	Ramsay AG, Johnson AJ, Lee AM, et al: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 118:2427–2437. 2008.
8	Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ and Baxter AG: NKT cells: facts, functions and fallacies. Immunol Today. 21:573–583. 2000.
9	Joyce S: CD1d and natural T cells: how their properties jump-start the immune system. Cell Mol Life Sci. 58:442–469. 2001.
10	Pittet MJ, Speiser DE, Valmori D, Cerottini JC and Romero P: Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol. 164:1148–1152. 2000.
11	Ohkawa T, Seki S, Dobashi H, et al: Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8⁺ T cells. Immunology. 103:281–290. 2001.
12	Kronenberg M: Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 23:877–900. 2005.
13	Bendelac A, Savage PB and Teyton L: The biology of NKT cells. Annu Rev Immunol. 25:297–336. 2007.
14	Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N and Watarai H: The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol. 22:1–6. 2010.
15	Godfrey DI and Kronenberg M: Going both ways: immune regulation via NKT cells. J Clin Inv. 114:13792004.
16	Van der Vliet HJ, Molling JW, von Blomberg BM, et al: The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol. 112:8–23. 2004.
17	Nowak M and Stein-Streilein J: Invariant NKT cells and tolerance. Int Rev Immunol. 26:95–119. 2007.
18	Matsuda JL, Mallevaey T, Scott-Browne J and Gapin L: CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system. Curr Opin Immunol. 20:358–368. 2008.
19	Parekh VV, Wilson MT and Van Kaer L: iNKT-cell responses to glycolipids. CritRevImmunol. 25:183–213. 2005.
20	Salio M, Silk JD and Cerundolo V: Recent advances in processing and presentation of CD1 bound lipid antigens. Curr Opin Immunol. 22:81–88. 2010.
21	Venkataswamy MM and Porcelli SA: Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol. 22:68–78. 2010.
22	Swann JB, Coquet JM, Smyth MJ and Godfrey DI: CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol. 314:293–323. 2007.
23	Berzofsky JA and Terabe M: The contrasting roles of NKT cells in tumor immunity. Curr Mol Med. 9:667–672. 2009.
24	Dhodapkar MV: Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front Biosci. 14:796–807. 2009.
25	Hegde S, Fox L, Wang X and Gumperz JE: Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. Immunology. 130:471–483. 2010.
26	Exley M, Garcia J, Wilson SB, et al: CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology. 100:37–47. 2000.
27	Kitamura H, Iwakabe K, Yahata T, et al: The natural killer T(NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 189:1121–1128. 1999.
28	Tomura M, Yu WG, Ahn HJ, et al: A novel function of Valpha14⁺CD4⁺NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol. 163:93–101. 1999.
29	Hayakawa Y, Takeda K, Yagita H, et al: Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol. 166:6012–6018. 2001.
30	Berzins SP, Smyth MJ and Baxter AG: Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 11:131–142. 2011.
31	Troy AJ, Summers KL, Davidson PJT, Atkinson CH and Hart DNJ: Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res. 4:585–593. 1998.
32	Enk AH, Jonuleit H, Saloga J and Knop J: Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer. 73:309–316. 1997.
33	Nestle FO, Burg G, Fäh J, Wrone-Smith T and Nickoloff BJ: Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol. 150:641–651. 1997.
34	Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D and Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 3:483–490. 1997.
35	Guo W, Xing C, Dong A, et al: Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia. Cancer Biol Ther. 14:916–921. 2013.
36	Spada FM, Borriello F, Sugita M, et al: Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells. Eur J Immunol. 30:3468–77. 2000.
37	Kurts C, Robinson BW and Knolle PA: Cross-priming in health and disease. Nat Rev Immunol. 10:403–414. 2010.
38	Matzinger P: The danger model: a renewed sense of self. Science. 296:301–5. 2002.
39	Burgdorf S, Schölz C, Kautz A, Tampé R and Kurts C: Spatial and mechanistic separation of cross-presentation endogenous antigen presentation. Nature Immunology. 9:558–566. 2008.
40	East JE, Sun W and Webb TJ: Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells. J Vis Exp. 29:43332012.
41	Webb TJ, Bieler JG, Schneck JP and Oelke M: Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. J Immunol Methods. 31:38–44. 2009.
42	Webb TJ, Giuntoli RL II, Rogers O, Schneck J and Oelke M: Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. Clin Cancer Res. 1:7652–7658. 2008.
43	Inaba H, Greaves M and Mullighan CG: Acute lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013.
44	Fais F, Tenca C, Cimino G, et al: CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia. 19:551–556. 2005.